Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
| Size/SKU | Availability | Price |
|---|---|---|
50 μg | Please contact Customer Service for Availability | CZK 17,100.00 |
About This Item
Form:
lyophilized powder
Assay:
>90% (SDS-PAGE)
Biological source:
human
Recombinant:
expressed in NSO cells
Mol wt:
predicted mol wt ~110 kDa
CZK 17,100.00
Please contact Customer Service for Availability
biological source
human
Quality Segment
recombinant
expressed in NSO cells
assay
>90% (SDS-PAGE)
form
lyophilized powder
potency
10-40 ng/mL ED50
mol wt
predicted mol wt ~110 kDa
packaging
pkg of 50 μg
storage condition
avoid repeated freeze/thaw cycles
impurities
endotoxin, tested
UniProt accession no.
storage temp.
−20°C
Gene Information
human ... KDR(3791)
Application
VEGF Receptor-2 (Flk-1, KDR)/Fc Chimera human is a homodimeric protein contains extracellular domain of human VEGF R2 (KDR) fused to the 6x histidine tagged Fc portion of human IgG1 by the peptide (EGF). The product was used to stuyd vasculogenesis and angiogenesis and as marker for pluripotent hematopoietic stem cells.[1]
Biochem/physiol Actions
VEGF Receptor-2 (VEGF R2) also known as Flk-1 or KDR belongs to class III subfamily of RTKs is a potent VEGF antagonist and is mainly expressed in endothelial cells. VEGF R2 can stimulate PLC-gamma pathway which in turn activate MAP kinase and subsequent strong signalling as well as can partly induces mitotic signals in NIH3T3 fibroblasts.[2] KDR also facilitates the release of nitric oxide in endothelial cells and assist in the regulation of the vasculature.[3]
VEGF receptors, class III receptor tyrosine kinases, have seven Ig like extracellular motifs and a tyrosine kinase intracellular domain split by a kinase insert sequence. VEGFR 1 and 2 are both expressed in an endothelial cell-specific manner.
Physical form
Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline containing 2.5 mg bovine serum albumin.
Analysis Note
The biological activity is measured by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells.
1 of 1
This Item | |||
|---|---|---|---|
| assay >90% (SDS-PAGE) | assay >90% (SDS-PAGE) | assay ≥90% (SDS-PAGE) | assay ≥95% (HPLC), ≥95% (SDS-PAGE) |
| biological source human | biological source human | biological source human | biological source human |
| recombinant expressed in NSO cells | recombinant expressed in baculovirus infected Sf21 cells | recombinant expressed in E. coli | recombinant expressed in HEK 293 cells |
| form lyophilized powder | form lyophilized powder | form lyophilized | form lyophilized |
| mol wt predicted mol wt ~110 kDa | mol wt predicted mol wt ~100 kDa | mol wt 15-16 kDa | mol wt 20.0-22.0 kDa |
| UniProt accession no. | UniProt accession no. | UniProt accession no. - | UniProt accession no. |
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.

